Loading...
News Category – Vivo News2019-10-20T17:42:02-07:00

Categories

VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China

January 9th, 2021|

Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in China

November 8th, 2018|
Go to Top